Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Human leukocyte antigen-A2-restricted CTL responses to mutated BRAF peptides in melanoma patients.

Cancer research - 15 Mar 2006

Somasundaram Rajasekharan, Swoboda Rolf, Caputo Laura, Otvos Laszlo, Weber Barbara, Volpe Patricia, van Belle Patricia, Hotz Susan, Elder David E, Marincola Francesco M, Schuchter Lynn, Guerry DuPont, Czerniecki Brian J, Herlyn Dorothee

Abstract excerpt

Mutated BRAF (BRAF(V600E)) is a potential immunotherapeutic target for melanoma because of its tumor specificity and expression in the majority of these lesions derived from different patients. BRAF(V600E) is expressed intracellularly and not on the cell surface, therefore providing a target for...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Epitopes, T-Lymphocyte
Share to HLA-A Antigens

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HLA-A2 Antigen

Share to Immunotherapy, Adoptive

Share to Lymphocyte Activation

Share to Melanoma

Share to Peptide Fragments

Share to T-Lymphocytes, Cytotoxic

Source

Identifiers

PMID: 16540682
DOI: 10.1158/0008-5472.CAN-05-1932

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-16540682-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Human leukocyte antigen-A2-restricted CTL responses to mutated BRAF peptides in melanoma patients.PMID 16540682Read ↗

CD4(+) T-cell recognition of mutated B-RAF in melanoma patients harboring the V599E mutation.Semantic proximity Read ↗

Binding and presentation of peptides derived from melanoma antigens MART-1 and glycoprotein-100 by HLA-A2 subtypes. Implications for peptide-based immunotherapy.Semantic proximity Read ↗

Immunogenicity of constitutively active V599EBRaf.Semantic proximity Read ↗

TCR Gene Transfer: MAGE-C2/HLA-A2 and MAGE-A3/HLA-DP4 Epitopes as Melanoma-Specific Immune TargetsSemantic proximity Read ↗

Multiple HLA-A alleles can present an immunodominant peptide of the human melanoma antigen Melan-A/MART-1 to a peptide-specific HLA-A*0201+ cytotoxic T cell line.Semantic proximity Read ↗

Identification of tumor-associated, MHC class II-restricted phosphopeptides as targets for immunotherapy.Semantic proximity Read ↗

Differences in phenotype and function between spontaneously occurring melan-A-, tyrosinase- and influenza matrix peptide-specific CTL in HLA-A*0201 melanoma patients.Semantic proximity Read ↗

Shifting the Balance of Activating and Inhibitory Natural Killer Receptor Ligands on BRAFV600E Melanoma Lines with Vemurafenib.Semantic proximity Read ↗

Immunohistochemistry with a mutation-specific monoclonal antibody as a screening tool for the BRAFV600E mutational status in primary cutaneous malignant melanoma.Semantic proximity Read ↗

Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma.Semantic proximity Read ↗

UV-induced N-ras mutations are T-cell targets in human melanoma.Semantic proximity Read ↗

A tyrosinase peptide presented by HLA-B35 is recognized on a human melanoma by autologous cytotoxic T lymphocytes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.